Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.

Thermobalancing therapy helps improve type-III CP/CPPS

03 Aug 2017

Thermobalancing therapy (TT) appears to be an effective treatment for type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), the most common type of prostatitis, suggests a recent study.

Furthermore, 6-month TT using Dr Allen’s therapeutic device (DATD) reduces CP/CPPS symptoms and improves quality of life (QoL), reduces prostatic volume, and increases maximum urinary flow rate.

To determine the effect of TT using DATD on CP/CPPS, the investigators measured National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume and maximum urinary flow rate in a cohort of patients (n=45) who underwent TT and a control group that did not have TT. Then, they compared the parameters between the two groups.

Based on baseline evaluation of both groups, there was no significant difference with regard to age, NIH-CPSI score, prostatic volume or maximum urinary flow rate. The two groups both showed a reduction in pain score. However, the difference between scores was significantly higher (8.72:1) in the treatment group than that in the nontreatment group.

QoL decreased significantly with TT, but in the control group there was just a slight decrease in QoL. TT markedly reduced prostatic volume, while in the control group prostatic volume increased. Moreover, TT increased maximum urinary flow rate in CP/CPPS patients, but it did not deliver a significant change in maximum urinary flow rate among those in the control group.

In another study, researchers found that TT with DATD is effective for benign prostatic hyperplasia, suggesting that blood circulation plays a crucial role in its cause. [Aging Male 2017;20:28-32]

Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.